PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

Francis J. Giles, Alan F. List, Michael Carroll, Jorge E. Cortes, Joyce Valickas, Bee Lian Chen, Eric Masson, Christian Jacques, Dirk Laurent, Maher Albitar, Eric J. Feldman, Gail J. Roboz

Research output: Contribution to journalArticle

Abstract

Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

Original languageEnglish (US)
Pages (from-to)891-897
Number of pages7
JournalLeukemia Research
Volume31
Issue number7
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Receptor Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Mucositis
Vascular Endothelial Growth Factor Receptor
vatalanib
Dyspepsia
Anorexia
Dizziness
Thrombocytopenia
Nausea
Vomiting
Fatigue
Appointments and Schedules

Keywords

  • Angiogenesis
  • Myelofibrosis
  • Tyrosine kinase inhibitor
  • VEGF

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. / Giles, Francis J.; List, Alan F.; Carroll, Michael; Cortes, Jorge E.; Valickas, Joyce; Chen, Bee Lian; Masson, Eric; Jacques, Christian; Laurent, Dirk; Albitar, Maher; Feldman, Eric J.; Roboz, Gail J.

In: Leukemia Research, Vol. 31, No. 7, 01.07.2007, p. 891-897.

Research output: Contribution to journalArticle

Giles, FJ, List, AF, Carroll, M, Cortes, JE, Valickas, J, Chen, BL, Masson, E, Jacques, C, Laurent, D, Albitar, M, Feldman, EJ & Roboz, GJ 2007, 'PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia', Leukemia Research, vol. 31, no. 7, pp. 891-897. https://doi.org/10.1016/j.leukres.2006.12.001
Giles, Francis J. ; List, Alan F. ; Carroll, Michael ; Cortes, Jorge E. ; Valickas, Joyce ; Chen, Bee Lian ; Masson, Eric ; Jacques, Christian ; Laurent, Dirk ; Albitar, Maher ; Feldman, Eric J. ; Roboz, Gail J. / PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. In: Leukemia Research. 2007 ; Vol. 31, No. 7. pp. 891-897.
@article{fd50381d74ef4d529ed0955664966f20,
title = "PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia",
abstract = "Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15{\%} of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3{\%}) and five (17{\%}) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.",
keywords = "Angiogenesis, Myelofibrosis, Tyrosine kinase inhibitor, VEGF",
author = "Giles, {Francis J.} and List, {Alan F.} and Michael Carroll and Cortes, {Jorge E.} and Joyce Valickas and Chen, {Bee Lian} and Eric Masson and Christian Jacques and Dirk Laurent and Maher Albitar and Feldman, {Eric J.} and Roboz, {Gail J.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.leukres.2006.12.001",
language = "English (US)",
volume = "31",
pages = "891--897",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

AU - Giles, Francis J.

AU - List, Alan F.

AU - Carroll, Michael

AU - Cortes, Jorge E.

AU - Valickas, Joyce

AU - Chen, Bee Lian

AU - Masson, Eric

AU - Jacques, Christian

AU - Laurent, Dirk

AU - Albitar, Maher

AU - Feldman, Eric J.

AU - Roboz, Gail J.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

AB - Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

KW - Angiogenesis

KW - Myelofibrosis

KW - Tyrosine kinase inhibitor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=34249826968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249826968&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.12.001

DO - 10.1016/j.leukres.2006.12.001

M3 - Article

C2 - 17560285

AN - SCOPUS:34249826968

VL - 31

SP - 891

EP - 897

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -